Literature DB >> 3719287

Sensory evoked potentials in Wilson's disease.

N S Chu.   

Abstract

Somatosensory, brainstem auditory and pattern-reversal visual evoked potentials (SEP, BAEP and VEP) were studied in 16 patients with Wilson's disease and 16 family members. In 13 patients with neurological manifestations, median nerve stimulation elicited cervical potentials with normal N13 latency. Scalp-recorded components of the median and tibial SEPs were absent bilaterally in 1 patient and unilaterally in another. The median conduction time (N13 to N20 peaks) was bilaterally prolonged in 3 patients and unilaterally prolonged in 5. In the tibial SEPs from 9 patients with neurological symptoms, the N22 latency of the lumbar evoked responses was within normal limits, but conduction time from N22 to P40 peaks was unilaterally prolonged in 5. Overall, 9 of 13 patients with neurological manifestations had SEP abnormalities. The BAEPs were bilaterally abnormal in 12 of 13 patients with neurological symptoms, mainly due to prolongation in the III-V and I-V intervals. In the VEPs from 8 patients with the neurological form, the P100 latency was delayed bilaterally in 2 patients and unilaterally in 1. Abnormalities in evoked potentials were not observed in 3 patients with other forms of Wilson's disease and in the family members. The present study indicates that the majority of the patients with neurological manifestations had subclinical dysfunction in three major sensory pathways. They are consistent with neuropathological and neuroradiological findings of widespread degeneration of the brain in Wilson's disease.

Entities:  

Mesh:

Year:  1986        PMID: 3719287     DOI: 10.1093/brain/109.3.491

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  12 in total

1.  Wilson's disease: cranial MRI observations and clinical correlation.

Authors:  S Sinha; A B Taly; S Ravishankar; L K Prashanth; K S Venugopal; G R Arunodaya; M K Vasudev; H S Swamy
Journal:  Neuroradiology       Date:  2006-06-03       Impact factor: 2.804

2.  Evoked potentials in patients with non-neurological Wilson's disease.

Authors:  I Aiello; G F Sau; R Cacciotto; M V Puliga; M E Lentinu; S Muzzu; D Posadinu; S Traccis
Journal:  J Neurol       Date:  1992-02       Impact factor: 4.849

3.  Penicillamine treatment of Wilson's disease and optic neuropathy.

Authors:  A H Lee; N F Lawton
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-08       Impact factor: 10.154

4.  Wilson's disease: normalisation of cortically evoked motor responses with treatment.

Authors:  B U Meyer; T C Britton; R Benecke
Journal:  J Neurol       Date:  1991-09       Impact factor: 4.849

5.  Standard neurodiagnostic tests in Sydenham's chorea.

Authors:  R F Gledhill; P D Thompson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-06       Impact factor: 10.154

6.  [Classification of Wilson's disease based on neurophysiological parameters].

Authors:  W Hermann; P Günther; A Wagner; T Villmann
Journal:  Nervenarzt       Date:  2005-06       Impact factor: 1.214

7.  Improvement of Diffusion Tensor Imaging (DTI) Parameters with Decoppering Treatment in Wilson's Disease.

Authors:  A Lawrence; J Saini; S Sinha; S Rao; M Naggappa; P S Bindu; A B Taly
Journal:  JIMD Rep       Date:  2015-06-30

8.  [Electrophysiological impairment profile of patients with Wilson's disease].

Authors:  W Hermann; T Villmann; A Wagner
Journal:  Nervenarzt       Date:  2003-10       Impact factor: 1.214

9.  Do cytokines have any role in Wilson's disease?

Authors:  M K Goyal; S Sinha; S A Patil; V Jayalekshmy; A B Taly
Journal:  Clin Exp Immunol       Date:  2008-10       Impact factor: 4.330

10.  Late-onset choreoathetotic syndrome following heart surgery.

Authors:  Maria Grazia Passarin; Silvia Romito; Mirko Avesani; Franco Alessandrini; Giuseppe Petrilli; Francesco Santini; Laura Bertolasi; Annamaria Musso; Carmela Ebba Buffone; Sarah Ottaviani; Paolo Bovi; Giuseppe Moretto
Journal:  Neurol Sci       Date:  2009-10-28       Impact factor: 3.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.